From The University of Texas Medical Branch, Galveston, Texas; Real Life Sciences Inc., New York; CreakyJoints, Global Healthy Living Foundation, Upper Nyack, New York; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; Kinapse Ltd., London, UK.
P. Sunkureddi, MD, The University of Texas Medical Branch; S. Doogan, BA, Real Life Sciences Inc.; J. Heid, BA, Kinapse Ltd.; S. Benosman, DVM, PhD, Kinapse Ltd.; A. Ogdie, MD, MSCE, Perelman School of Medicine at the University of Pennsylvania; L. Martin, RN, CreakyJoints, Global Healthy Living Foundation; J.B. Palmer, PharmD, Novartis Pharmaceuticals Corporation.
J Rheumatol. 2018 May;45(5):638-647. doi: 10.3899/jrheum.170500. Epub 2018 Feb 15.
To evaluate the types of experiences and treatment access challenges of patients with psoriatic arthritis (PsA) using self-reported online narratives.
English-language patient narratives reported between January 2010 and May 2016 were collected from 31 online sources (general health social networking sites, disease-focused patient forums, treatment reviews, general health forums, mainstream social media sites) for analysis of functional impairment and 40 online sources for assessment of barriers to treatment. Using natural language processing and manual curation, patient-reported experiences were categorized into 6 high-level concepts of functional impairment [social, physical, emotional, cognitive, role activity (SPEC-R), and general] and 6 categories to determine barriers to treatment access (coverage ineligibility, out-of-pocket cost, issues with assistance programs, clinical ineligibility, formulary placement/sequence, doctor guidance). The SPEC-R categorization was also applied to 3 validated PsA patient-reported outcome (PRO) instruments to evaluate their capacity to collect lower-level subconcepts extracted from patient narratives.
Of 15,390 narratives collected from 3139 patients with PsA for exploratory analysis, physical concepts were the most common (81.5%), followed by emotional (50.7%), cognitive (20.0%), role activity (8.1%), and social (5.6%) concepts. Cognitive impairments and disease burden on family and parenting were not recorded by PsA PRO instruments. The most commonly cited barriers to treatment were coverage ineligibility (51.6%) and high out-of-pocket expenses (31.7%).
Patients often discussed physical and emotional implications of PsA in online platforms; some commonly used PRO instruments in PsA may not identify cognitive issues or parenting/family burden. Nearly one-third of patients with PsA reported access barriers to treatment.
通过患者自我报告的在线叙述,评估患有银屑病关节炎(PsA)患者的体验类型和治疗可及性挑战。
从 31 个在线来源(一般健康社交网络、疾病聚焦型患者论坛、治疗评论、一般健康论坛、主流社交媒体网站)收集 2010 年 1 月至 2016 年 5 月期间发表的英文患者叙述,用于分析功能障碍,并从 40 个在线来源评估治疗障碍。使用自然语言处理和手动策展,将患者报告的体验分类为 6 个高级功能障碍概念[社会、身体、情感、认知、角色活动(SPEC-R)和一般]和 6 个确定治疗可及性障碍的类别(保险覆盖范围不合格、自付费用、援助计划问题、临床不合格、处方放置/顺序、医生指导)。SPEC-R 分类也应用于 3 种经过验证的 PsA 患者报告结局(PRO)工具,以评估它们从患者叙述中提取较低级别子概念的能力。
从 3139 名患有 PsA 的患者中收集了 15390 个叙述进行探索性分析,身体概念是最常见的(81.5%),其次是情感(50.7%)、认知(20.0%)、角色活动(8.1%)和社会(5.6%)概念。认知障碍和疾病对家庭和育儿的负担未被 PsA PRO 工具记录。治疗最常被提及的障碍是保险范围不合格(51.6%)和自付费用高(31.7%)。
患者经常在在线平台上讨论 PsA 的身体和情感影响;一些常用于 PsA 的 PRO 工具可能无法识别认知问题或育儿/家庭负担。近三分之一的 PsA 患者报告治疗存在障碍。